FDA
-
-
-
-
-
-
-
Dare Bioscience launches Flora Sync LF5 vaginal probiotic capsules
-
-
-
-
-
-
-
Daré Bioscience reports interim Phase 3 results for hormone-free contraceptive
-
-
-
-
-
-
-
Dare Bioscience gets FDA clearance for HPV treatment phase 2 trial
-
-
-
-
-
-
-
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
-
-
-
-
-
-
-
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
-
-
-
-
-
-
-
Daré Bioscience reports interim Phase 3 results for hormone-free contraceptive
-
-
-
-
-
-
-
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
-
328,605 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

